Skip to main content
Premium Trial:

Request an Annual Quote

How Low Can They Go?


For the GTI companies, the 52-week high is a distant memory

By Adrienne Burke

One look at the graph at the right will tell you February wasn’t a great month for the GTI. Heading into March, things didn’t look much better. As this issue of Genome Technology went to press, four GTI stocks had just hit their 52-week lows. Three — Compugen at $4.87, Cepheid at $4.75, and Lion at $34 — only went public in the past year. This was rock bottom. The fourth, Aurora, has actually seen far grimmer days (in the $3 range) since it went public in 1997.

Another five companies — Aclara, Orchid, Rosetta, Sequenom, and Variagenics — hovered within 10 percent of their 52-week low on March 2.

More painful for anyone who’s been holding onto these companies is to recall their 52-week highs. Sequenom was worth just six percent of the high it reached a year ago — $11.75 vs. $191.25. Aclara and Nanogen were worth seven percent of their high trading prices. Aurora was at 11 percent and Orchid 12 percent its 52-week high.

To carry out our futile analysis of the day further: On the flip side are eight companies that closed at values at least 50 percent better than their 52-week low: Applied Biosystems, Bruker Daltonics, Celera, Illumina, Invitrogen, Luminex, Lynx, and Molecular Devices.

Investors who bought Luminex when it was down at $13.25 were 142 percent better off at close of business March 2. Invitrogen, at $80.88, was worth 124 percent more than its low. And Molecular Devices closed at $66 per share — up 74 percent from its low of $38.

And while there’s not a GTI stock that hasn’t disappointed lately, a few aren’t such heartbreakers. Luminex and Molecular Devices are still worth 50 percent of their high value. And Invitrogen wins for best behavior of all: it’s worth 81 percent its 52-week high of $99.50. Could it be that mad cow tests — Invitrogen’s hot product at the moment — make more sense to investors than genomics technologies?

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.